ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 246,13
0,71%
Dow Jones
39 387,76
0,85%
DAX
18 782,98
0,55%
Brent Oil
84,195
0,29%
Bitcoin
62 935,09
-0,18%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BiondVax Pharmaceuticals Ltd (BVXV)

  7. BiondVax Pharmaceuticals Ltd (BVXV) Actualités

BVXV

BiondVax Pharmaceuticals (BVXV)

BiondVax Pharmaceuticals Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BVXV
DateHeureSourceTitreSymboleSociété
30/04/202422h06Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
16/04/202423h27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
10/04/202413h00PR Newswire (US)Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202421h17Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202413h00PR Newswire (US)Scinai leadership to attend BIO-Europe Spring 2024NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
13/02/202413h00PR Newswire (US)Scinai Welcomes Liat Halpert as Head of Business Development and SalesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
04/01/202422h01PR Newswire (US)Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
20/11/202313h30PR Newswire (US)Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity RuleNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/09/202323h27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/09/202312h00GlobeNewswire Inc.BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological TherapeuticsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
28/08/202322h01Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
28/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202322h16Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202316h07Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/08/202315h00GlobeNewswire Inc.BiondVax Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
01/08/202322h01GlobeNewswire Inc.Nasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/07/202314h17GlobeNewswire Inc.IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/06/202322h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
05/06/202313h00GlobeNewswire Inc.BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
15/05/202323h05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
17/04/202322h52Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
17/04/202322h25GlobeNewswire Inc.BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business UpdateNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/04/202315h13Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
16/03/202318h10GlobeNewswire Inc.BiondVax to Present at BIO-Europe SpringNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/03/202320h07GlobeNewswire Inc.IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research InstitutesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
02/02/202320h15GlobeNewswire Inc.BiondVax Presenting at BIO CEO & Investor ConferenceNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/01/202315h45Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/01/202314h17Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/01/202312h25GlobeNewswire Inc.BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/01/202313h15GlobeNewswire Inc.BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:BVXV

Dernières Valeurs Consultées

EU
PX1
CAC 40
NYSE
MRK
Merck
EU
MC
Lvmh Moet Hennessy Louis...
EU
ORA
Orange
USI
USTECH100
US Tech 100
COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
EU
RI
Pernod Ricard
EU
EN
Bouygues
NYSE
JPM
JP Morgan Chase
NASDAQ
AMZN
Amazon.com
EU
ML
Michelin
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés